publication date: Jul. 2, 2020
Issue 27 - Jul. 2, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Conversation with The Cancer Letter

    Northwell Health reopens cancer services after COVID-19 deluge

    New York health system explores NCI designation in affiliation with Cold Spring Harbor Laboratory

    Any way you look at it, Northwell Health, New York’s largest health system, took a massive hit from COVID-19.

    Northwell has treated over 50,000 COVID patients, admitting over 15,000 of them to its hospitals—more than any such system in the U.S.

  • NCI BSA approves nine new and reissue concepts

    The NCI Board of Scientific Advisors has approved nine new and reissue concepts—Request for Applications, Cooperative Agreement, Request for Proposals, and Program Announcements with special receipt, referral and review.

  • In Brief

    • Yale Cancer Center receives $2.8M NCI cancer systems immunology grant
    • USC Norris receives $5 million for cancer drug discoveries
    • Alexander Drilon named chief of the Early Drug Development Service at MSK
    • Nancy R. Daly named CEO of Conquer Cancer, the American Society of Clinical Oncology Foundation
    • ASCO’s Association for Clinical Oncology establishes PAC
    • Florida Cancer Specialists & Research Institute breaks ground for new location
  • TCCL Logo

  • Trials & Tribulations

    (Social + geographic) distance = Ongoing challenges in disparities for rural cancer patients

    Approximately two-thirds of the NCI Community Oncology Research Programs, serve states in which the rural population exceeds 30%. 

  • Clinical Roundup

    • NCCN Guidelines for patients can help patients recognize side-effects of immunotherapy
  • Drugs & Targets

    • Phesgo receives FDA approval in breast cancer indication for at home treatment
    • Keytruda receives FDA approval as first-line immunotherapy for MSI-H/dMMR MCC
    • Bavencio receives FDA approval for urothelial carcinoma maintenance treatment
    • Reblozyl approved by European Commission for transfusion-dependent anemia in adults with MDS or beta thalassemia
    • Guardant Health launches real-world clinical-genomic platform to accelerate precision oncology drug development
  • NCI Trials

    NCI Trials for July 2020

    The National Cancer Institute approved the following clinical research studies last month. 

    For further information, contact the principal investigator listed.

Copyright (c) 2020 The Cancer Letter Inc.